Veracyte Acquires Decipher Biosciences
February 3, 2021
Veracyte, Inc. has entered into a definitive agreement to acquire Decipher Biosciences, a commercial-stage precision oncology company focused on urologic cancers, for $600 million in total consideration ($250 million cash and up to $350 million in stock). The acquisition expands Veracyte’s genomic cancer diagnostics menu, adds Decipher’s commercial tests and data assets, and is expected to accelerate revenue growth and global market reach.
- Buyers
- Veracyte, Inc.
- Targets
- Decipher Biosciences, Inc.
- Sellers
- Decipher Biosciences security holders
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Veracyte Acquires Convergent Genomics to Expand Urinary Tumor DNA Bladder Cancer Diagnostics
September 14, 2026
Healthcare Services
Veracyte announced its acquisition of Convergent Genomics to add the UroAmp urinary tumor DNA (utDNA) platform to its cancer diagnostics portfolio. The technology is intended to help guide non-muscle-invasive bladder cancer care by enabling urine-based therapy-response monitoring and post-treatment surveillance.
-
Ono Pharmaceutical Acquires Deciphera Pharmaceuticals
June 12, 2024
Pharmaceuticals
Ono Pharmaceutical Co., Ltd. completed its previously announced tender offer to acquire all outstanding shares of Deciphera Pharmaceuticals Inc. for $25.60 per share, totaling approximately $2.4 billion. Following the tender offer, a wholly-owned subsidiary merged with and into Deciphera, with Deciphera surviving as a wholly owned subsidiary of Ono.
-
Veracyte to Acquire C2i Genomics to Add Whole-Genome MRD Capabilities
January 8, 2024
Healthcare Services
Veracyte has reached a definitive agreement to acquire C2i Genomics, a minimal residual disease (MRD) detection company, to add whole-genome MRD capabilities to its diagnostics platform. Under the terms, Veracyte will pay $70 million in Veracyte shares at closing and up to an additional $25 million tied to future performance milestones, expected to close in the first quarter of 2024.
-
Vertex Pharmaceuticals Acquires ViaCyte for $320M
July 11, 2022
Biotechnology
Vertex Pharmaceuticals agreed to acquire clinical-stage cell therapy company ViaCyte for $320 million in cash. The deal gives Vertex additional stem cell lines, IP and GMP manufacturing capabilities intended to accelerate its VX-880 and other cell replacement therapy programs for type 1 diabetes.
-
Verdesian Life Sciences Acquires Cytozyme Laboratories
April 27, 2021
Agriculture
Verdesian Life Sciences has acquired Cytozyme Laboratories, Inc.; Cascadia Capital served as exclusive financial advisor to Cytozyme. The acquisition brings together complementary biological and nutritional crop technologies to expand Verdesian's product portfolio and support sustainable yield solutions for growers.
-
OncoCyte Corporation Acquires Insight Genetics
January 10, 2020
Healthcare Services
OncoCyte Corporation agreed to acquire all outstanding capital stock of Insight Genetics, a privately held molecular diagnostics company, for approximately $12 million in cash and stock plus potential contingent payments. The acquisition adds Insight Genetics' IM Score immuno-oncology diagnostic test and a pharma-trial–capable CLIA/CAP lab to OncoCyte's portfolio to expand its capabilities in oncology diagnostics and pharma services.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.